Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17448827 | 0.82 | HCRTR2 (0.48) | HCRTR1HCRTR2 | |
| SCHEMBL12150154 | 0.80 | HCRTR2 (0.45) | HCRTR1HCRTR2 | |
| SCHEMBL17448828 | 0.80 | HCRTR1 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL17069779 | 0.79 | HCRTR1 (0.51) | HCRTR1HCRTR2 | |
| SCHEMBL17069777 | 0.79 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL30006500 | 0.78 | ALDH1A1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL1586233 | 0.78 | ALDH1A1 (0.56) | HCRTR1HCRTR2 | |
| SCHEMBL17069769 | 0.78 | HCRTR2 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL18160582 | 0.78 | HCRTR2 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL18195532 | 0.78 | MYC (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975876-B2 | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975876-B2 | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9745284-B2 | 2-pyridyloxy-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-08-29 | — | — | US | disclosed |
| US-9556145-B2 | 2-pyridyloxy-4-ester orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556145-B2 | 2-pyridyloxy-4-ester orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160214960-A1 | 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160068514-A1 | HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-01-21 | — | — | US | disclosed |
| US-8653260-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8399480-B2 | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-8247415-B2 | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028481-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | HCRTR1 527/4885HCRTR2 330/4885 |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | HCRTR1 527/4885HCRTR2 330/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | HCRTR1 527/4885HCRTR2 330/4885 |
| US-20160068514-A1 | HALO AND TRIFLUOROMETHYL SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160214960-A1 | 2-PYRIDYLOXY-4-ESTER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160304490-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | HCRTR1 2/4885HCRTR2 1/4885 |
| US-20160016935-A1 | 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.